Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group

Burns Clinical Trial

Official title:

Prospective Evaluation of the Effects of Topical Therapy With Sulfamylon® For 5% Topical Solution on Autograft Healing in Subjects With Thermal Injuries Requiring Meshed Autografts: A Comparison to a Historical Control Group

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00634166
• Other study ID #: SMS-401
• Status: Terminated
• Phase: Phase 4
• Start date: September 2007
• Est. completion date: April 2014

Study information

• Verified date: September 2022
• Source: Viatris Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective is to compare the effectiveness of treatment with Sulfamylon® solution as the initial topical moist dressing over meshed autografts following the initial graft procedure on preventing graft loss in a prospective cohort of subjects versus a historical control group in a non-inferiority trial.

Description:

This is a prospective, non-inferiority, multi-center, historically controlled, open label study that will evaluate the effects of topical therapy with Sulfamylon® For 5% Topical Solution on autograft healing in subjects with thermal injuries requiring meshed autografts against a similar historic control population in which Sulfamylon® For 5% Topical Solution or mafenide acetate or other mafenide salt forms were not used. Prospective subjects meeting the entrance criteria will receive Sulfamylon® solution as topical antimicrobial treatment on moist dressings following initial meshed autograft procedure (Day 1). Sulfamylon® solution will be used every 6-8 hours, or as needed, to keep the dressing moist. The graft will be evaluated on Days 5-7, Days 12-14 and Days 18-21, unless the subject is discharged, dies, or experiences graft loss / regrafting of the initial meshed autograft prior to Assessment 4 (Days 18-21).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 220
• Est. completion date: April 2014
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Months and older

Eligibility

Inclusion Criteria:

In order for prospective subjects to be eligible for entry into the study:

• Subjects must have thermal injuries of 20-60% TBSA requiring at least one meshed autograft on the chest, abdomen, or proximal upper and lower extremities following surgical excision of the burn injury. Refer to Supplement 20.3.2: Lund Browder charts

• Subjects may be male or female, 3 months of age or older

• Females of childbearing potential must have a negative urine pregnancy test upon admission and agree to avoid pregnancy throughout the course of the study. Since this population is hospitalized for the duration of the study, an agreement of sexual abstinence is appropriate for this trial. Those subjects who do not wish to commit to sexual abstinence for the duration of this study must agree to avoid pregnancy by using a medically supervised method of contraception (such as hormonal contraception in conjunction with a vaginal spermicide or a tubal ligation at least 3 months prior to study entry)

• Subjects must be willing and able to provide written informed consent. If subjects are unable to provide written informed consent, then the subject's legally acceptable representative may provide written informed consent in accordance with the IRB/IEC, and federal, state and local regulations.

Exclusion Criteria:

Prospective subjects will be excluded from the study for the following reasons:

• Non-thermal burn injuries

• Inhalation injuries resulting in a PaO2 /FIO2 ratio < 300 mmHg on more than one arterial blood gas in the first 48 hours post-admission

• Females who are currently pregnant or breast feeding, or who intend to become pregnant during the course of the study

• Subjects with acute renal failure

• Subjects with known systemic allergy to sulfonamides or to sulfur-containing medication

• Time interval between burn injury and excision and grafting is greater than 7 days

• Grafting procedures that are conducted and/or evaluated on an outpatient basis

• Inability to use a meshed autograft as part of the initial grafting procedure

• Inability to use SS5% as the only initial prophylactic topical antimicrobial therapy on meshed autografts

• Thermal burn injuries less than 20% or greater than 60% TBSA

• Subjects who are participating in any other clinical studies involving any investigational product, or who have participated in such a study within the previous 30 days

• Subjects with known glucose-6-phosphate dehydrogenase deficiency

Related Conditions & MeSH terms

• Burns

Intervention

Drug:
• Sulfamylon® For 5 % Topical Solution
Sulfamylon® For 5% Topical Solution is indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.
• Topical Antimicrobial/Antifungal Medications
'Topical Antimicrobial/Antifungal Medications' Various topical antimicrobials and antifungals include: Bacitracin; Amphotericin B; Silver Sulfadiazine; Cefazolin; Vancomycin; Nystatin; Fluconazole; Piperacillin Sodium with Tazobactam.

Locations

Country	Name	City	State
United States	John's Hopkins Burn Center	Baltimore	Maryland
United States	University of Missouri Healthcare - Dept. of Surgery	Columbia	Missouri
United States	Shands Burn Center - Univ. of Florida	Gainesville	Florida
United States	University of Kansas Medical Center	Kansas City	Kansas
United States	Loyola University Medical Center	Maywood	Illinois
United States	University of South Alabama Medical Center	Mobile	Alabama
United States	Arrowhead Regional Medical Center	Redlands	California
United States	The Plastic Surgery Institute - Southern Illinois Univ. School of Medicine	Springfield	Illinois
United States	Wake Forest University - Department of General Surgery	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Mylan Inc.	Mylan Bertek Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Graft Loss After Initial Meshed Autograft Procedure on Days 5-7.		The primary analysis will compare the percent of subjects with All Cause Graft Loss of the initial meshed autograft procedure at Days 5-7.
Secondary	Percentage of Participants With All-cause Graft Loss at Days 12 to 14 in the FAS Population	All cause graft loss is defined as graft adhesion of < 85% for the initial meshed autograft procedure.	Secondary analyses will include the percent of subjects with All Cause Graft Loss at Days 12-14
Secondary	Percentage of Participants With All-cause Graft Loss at Days 18 to 21 in the FAS Population	All cause graft loss is defined as graft adhesion of < 85% for the initial meshed autograft procedure.	Days 18 to 21
Secondary	Percentage of Participants With Treatment Failure at Days 5 to 7 in the FAS Population	Treatment failure is defined as a change in topical antimicrobial therapy of initial meshed autograft due to suspected infection within the first 7 days or infectious graft loss.	Days 5-7
Secondary	Percentage of Participants With Infectious Graft Loss at Days 5 to 7 in the FAS Population	Graft adhesion of < 85% for the initial meshed autograft procedure due to infection.	Days 5-7
Secondary	Percentage of Participants With Infectious Graft Loss at Days 12 to 14 in the FAS Population	Graft adhesion of < 85% for the initial meshed autograft procedure due to infection.	Days 12-14
Secondary	Percentage of Participants With Infectious Graft Loss at Days 18 to 21 in the FAS Population	Graft adhesion of < 85% for the initial meshed autograft procedure due to infection.	Days 18-21